gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · DXRHealthcareSurgical Instruments

Daxor Corporation Common Stock (DXR)

$8.91+2.44%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$8.91▼ 33.98% in range
Nov 4, 2025Low $8.70 · High $14.75Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Daxor closed at $8.91 on Nov 4, up 2.44%, within 2.4% of its lowest close since Sep 29. Volume of 11.0K shares was 0.88× its 20-day average (close to normal).

Split-adjusted performance: -13.5% over one month, -12.1% over six months.

In the quarter ended Dec 31, 2011, revenue was $369.83K, up 2.3% from a year earlier, with a net margin of -403.2%.

Short interest was 3.4K shares at the Oct 15 settlement, down 51.5% from the prior report (0.1% of float, 1.0 days to cover).

Market cap$52.0M5.8M shares
Revenue · quarter$369.8K+2.3% YoY
Diluted EPS$-0.35−166.0% YoY
P/E · TTM—
Net margin-403.2%Gross 52.2%
Dividend yieldNone$0.03 last paid
Range since Sep 298.70 – 14.75−39.6% from high
Volume11.0K0.88× 20-day avg
Volatility · 60d43.0%Annualised
Short % of float0.1%1.0 days to cover
Net cash$18.7MCash $55.9M
Next earnings—Not scheduled
Split-adjusted performance
1W −0.6%1M −13.5%3M −15.0%6M −12.1%YTD −39.6%1Y —3Y +13.9%5Y −16.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum44
Revenue growth32
Net margin12
Value (low P/E)—
Size33

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short3.4K−51.5% vs prior
Days to cover1.0Settled Oct 15
% of float0.1%
Short vol. 10d26.2%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
DXRDaxor$8.91+2.44%−12.1%+2.3%−403.2%—$52.0M
SRTSSensus Healthcare$3.25−1.07%−20.5%−68.7%−382.1%—$53.5MCompare
SNWVSANUWAVE Health$5.73−3.37%−64.0%−3.1%−7.0%3.4$49.3MCompare
MDAISpectral AI$1.53+2.00%−31.1%−30.4%−118.5%—$49.2MCompare
CVRXCVRx$1.58+14.49%−77.7%+15.6%−89.4%—$42.1MCompare
XTNTXtant Medical Holdings$0.2960+6.47%−48.7%−35.0%−40.9%—$41.5MCompare
TELATELA Bio$0.8378+4.46%−15.4%−4.5%−58.4%—$37.8MCompare
LNSRLENSAR$5.84+4.85%+8.4%+18.4%10.7%4.6$71.7MCompare
SKINSkinHealth Systems$11.05+6.76%−40.8%−7.8%−3.7%—$72.0MCompare

News about Daxor

All news →
Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in KansasGlobeNewswire Inc. · Jul 30, 2026▲ PositiveDaxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, TexasGlobeNewswire Inc. · Jul 7, 2026▲ Positive

Quick answers

What does Daxor do?
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
What is DXR's market cap?
$52.03M, based on the Nov 4 close of $8.91.
Does Daxor pay a dividend?
No regular cash dividend has been paid in the last year.
How much of DXR is sold short?
3.4K shares, 0.1% of float, as of Oct 15, 2026.
What sector is DXR in?
Healthcare, in the Surgical Instruments industry.

About Daxor

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. The company operates as a single business segment centered on the development, commercialization, and support of its proprietary blood volume analysis technology used by healthcare providers.

HQ: New York, NY750 employeesListed Jul 25, 1983daxor.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology